Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

Fig. 5

ZT55 suppresses the tumorigenicity of HEL cells in xenograft mouse model. Nude mice bearing established HEL xenograft tumors (~ 100 mm3) orally administered with 100 mg/kg ZT55 or vehicle control once a day for 2 weeks. (a) The tumor volumes and (b) body weight of mice were measured at the indicated time after ZT55 administration. (c) The tumor weights were measured to comparison. (d) Xenograft tumors were taken photos. (e) The proliferation and apoptosis of xenograft tumor cells were measured with H&E staining and TUNEL assay, respectively. Bar = 100 μm. Data are presented as mean ± SEM (n = 8), *p < 0.05, **p < 0.01 compared with the vehicle control group

Back to article page